Dopamine transporter SPECT imaging in parkinson disease and dementia

Devaki Shilpa Surasi, Patrick J. Peller, Zsolt Szabo, Gustavo Mercier, Rathan Subramaniam

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

The diagnosis of Parkinson disease (PD) and dementia with Lewy bodies (DLB) is often not straightforward. When PD symptoms are atypical or overlap with other diseases (eg, essential tremor [ET] or drug induced), [123I] N-ω-fluoropropyl-2β-carbomethoxy-3b-(4-iodophenyl) nortropane ([ 123I]FP-CIT) single-photon emission computed tomography (SPECT) can improve the diagnostic accuracy. The potential side effects of medications for PD may be avoided, if [123I]FP-CIT SPECT is normal. [ 123I]FP-CIT SPECT is helpful in the diagnosis of DLB, differentiating it from other causes of dementia such as Alzheimer disease (AD).

Original languageEnglish (US)
Pages (from-to)459-467
Number of pages9
JournalPET Clinics
Volume8
Issue number4
DOIs
StatePublished - Oct 2013

Keywords

  • Dementia
  • Dopamine
  • Parkinson disease
  • SPECT

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Dopamine transporter SPECT imaging in parkinson disease and dementia'. Together they form a unique fingerprint.

  • Cite this

    Surasi, D. S., Peller, P. J., Szabo, Z., Mercier, G., & Subramaniam, R. (2013). Dopamine transporter SPECT imaging in parkinson disease and dementia. PET Clinics, 8(4), 459-467. https://doi.org/10.1016/j.cpet.2013.08.006